VEGF and bFGF Gene Polymorphisms in Patients with Non-Hodgkin's Lymphoma

Table 3

Patients characteristics with respect to the detected associations with the VEGF T and bFGF G variants in comparison with healthy population. The bFGF G variant was more frequently detected among patients with aggressive histological subtype of NHL. The VEGF T variant was more frequently detected among patients presented with high IPI. Individuals carrying the VEGF T variant are over three times more likely to develop NHL characterized by the highest IPI score, while those with the bFGF G allele are over twice more likely to present with aggressive histological type of the disease.

NHL patients	𝑁	VEGF pp. 936		bFGF pp. −921
		CC	T	CC	G
		𝑛 (%)	𝑛 (%)	𝑛 (%)	𝑛 (%)
IPI risk groups
Low/intermediate low (1, 2)	40	35; (87.5%)	5§; (12.5%)	31; (77.5%)	9; (22.5%)
Intermediate high/high (3, 4)	38	26; (68.4%)	12§,¶; (31.6%)	26; (68.4%)	12; (31.6%)
Low/intermediate (1–3)	61	51; (83.6%)	10^#; (16.4%)	46; (75.4%)	15; (24.6%)
High (4)	17	10; (59%)	7^#,**; (41%)	11; (64.7%)	6; (35.3%)
Histological aggressiveness
Indolent	40	31; (77.5%)	9; (22.5%)	33; (82.5%)	7^†; (17.7%)
Aggressive	38	30; (78.9%)	8; (21.1%)	24; (63.2%)	14^†,‡; (36.8%)
Patients	78	61; (78.2%)	17; (21.8%)	57; (73%)	21*; (27%)
Healthy individuals	122	101; (82.8%)	21¶,∗∗; (17.2%)	99; (81.1%)	23^*,‡; (18.9%)

NHL: non-Hodgkin's lymphoma; IPI: International Prognostic Index; *(NHL patients versus controls) OR = 1.61, 𝑃=0.24; ^†(patients with aggressive versus patients with indolent disease) 𝑃=0.095; ^‡(patients with aggressive disease versus controls) OR = 2.51, 𝑃=0.038; §(patients with intermediate high/high IPI (3, 4) versus low/intermediate low IPI (1, 2)) 𝑃=0.077; ¶(patients with intermediate high/high IPI (3, 4) versus controls) OR = 2.22, 𝑃=0.093; ^#(patients with high (4) versus low/intermediate (1–3) IPI) 𝑃=0.044; **(patients with high IPI (4) versus controls) OR = 3.37, 𝑃=0.029.